Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Ren, Fang ^a   Shi, Huirong ^a   Zhang, Gong ^a   Zhang, Ruitao ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Deleted in liver cancer 1; Invasion; Metastasis; Ovarian cancer; Plasminogen activator inhibitor 1; Prognosis

Indexed keywords

DELETED IN LIVER CANCER 1 PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASCITES; CANCER PROGNOSIS; CANCER STAGING; CYSTADENOCARCINOMA; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, SEROUS; FEMALE; GTPASE-ACTIVATING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84884549249     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-60     Document Type: Article

References (37)

1. Ovarian cancer: an overview. Roett MA, Evans P, Am Fam Physician 2009 80 609 616 19834990
2. Therapeutic strategies in epithelial ovarian cancer. Kim A, Ueda Y, Naka T, Enomoto T, J Exp Clin Cancer Res 2012 13 31 14
3. Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals. Chen SS, Michael A, Butler-Manuel SA, Discov Med 2012 13 7 17 22284780
4. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Kim TY, Vigil D, Der CJ, Juliano RL, Cancer Metastasis Rev 2009 28 77 83 10.1007/s10555-008-9167-2 19221866
5. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Liao YC, Lo SH, Int J Biochem Cell Biol 2008 40 843 847 10.1016/j.biocel.2007. 04.008 17521951 (Pubitemid 351329658)
6. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Kim TY, Lee JW, Kim HP, Jong HS, Kim TY, Jung M, Bang YJ, Biochem Biophys Res Commun 2007 355 72 77 10.1016/j.bbrc.2007.01.121 17292327 (Pubitemid 46273368)
7. Effect of FAK, DLC-1 gene expression on OVCAR-3 proliferation. Liu H, Shi H, Hao Y, Zhao G, Yang X, Wang Y, Li M, Liu M, Mol Biol Rep 2012 39 10665 10670 10.1007/s11033-012-1956-6 23079702
8. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cesari M, Pahor M, Incalzi RA, Cardiovasc Ther 2010 28 72 e91 10.1111/j.1755-5922.2010. 00171.x 20626406
9. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Gramling MW, Church FC, Thromb Res 2010 125 377 381 10.1016/j.thromres.2009.11.034 20079523
10. Linking cell structure to gene regulation: signaling events and expression controls on the model genes PAI-1 and CTGF. Samarakoon R, Goppelt-Struebe M, Higgins PJ, Cell Signal 2010 22 1413 1419 10.1016/j.cellsig.2010.03.020 20363319
11. New role of plasminogen activator inhibitor-1 in alcohol-induced liver injury. Arteel GE, J Gastroenterol Hepatol 2008 23 Suppl 1 54 S59 18336665
12. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Czekay RP, Loskutoff DJ, Exp Biol Med (Maywood) 2004 229 1090 1096 (Pubitemid 39602250)
13. Plasminogen activator inhibitor-1 in the pathogenesis of asthma. Cho SH, Ryu CH, Oh CK, Exp Biol Med (Maywood) 2004 229 138 146 (Pubitemid 38146557)
14. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Whitley BR, Palmieri D, Twerdi CD, Church FC, Exp Cell Res 2004 296 151 162 10.1016/j.yexcr.2004.02.022 15149846 (Pubitemid 38624637)
15. Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells. Shih YP, Takada Y, Lo SH, Mol Cancer Res 2012 10 34 39 10.1158/1541-7786.MCR-11-0450 22064653
16. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Remmele W, Stegner HE, Pathologe 1987 8 138 140 3303008
17. Biomarkers for ovarian cancer detection and therapy. Dutta S, Wang FQ, Phalen A, Fishman DA, Cancer Biol Ther 2010 9 668 677 10.4161/cbt.9.9.11610 20372062
18. Significance of lymphovascular space invasion in epithelial ovarian cancer. Matsuo K, Sheridan TB, Yoshino K, Miyake T, Hew KE, Im DD, Rosenshein NB, Mabuchi S, Enomoto T, Kimura T, Sood AK, Roman LD, Cancer Med 2012 1 156 164 10.1002/cam4.31 23342265
19. Gene structure, tissue expression, and linkage mapping of the mouse DLC-1 gene (Arhgap7). Durkin ME, Yuan BZ, Thorgeirsson SS, Popescu NC, Gene 2002 288 119 127 10.1016/S0378-1119(02)00462-6 12034501 (Pubitemid 34595369)
20. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC, Clin Cancer Res 2006 12 1412 1419 10.1158/1078-0432.CCR-05-1906 16533763
21. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Kim TY, Jong HS, Song SH, Dimtchev A, Jeong SJ, Lee JW, Kim TY, Kim NK, Jung M, Bang YJ, Oncogene 2003 22 3943 3951 10.1038/sj.onc.1206573 12813468 (Pubitemid 36819668)
22. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, Srivastava G, Sidransky D, Califano J, Steenbergen RD, Rha SY, Tan J, Hsieh WS, Ambinder RF, Lin X, Chan AT, Tao Q, Oncogene 2007 26 934 944 10.1038/sj.onc.1209839 16862168
23. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Goodison S, Yuan J, Sloan D, Kim R, Li C, Popescu NC, Urquidi V, Cancer Res 2005 65 6042 6053 10.1158/0008-5472.CAN-04-3043 16024604 (Pubitemid 40994388)
24. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Yuan BZ, Durkin ME, Popescu NC, Cancer Genet Cytogenet 2003 140 113 117 10.1016/S0165-4608(02)00674-X 12645648 (Pubitemid 36349010)
25. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Yuan BZ, Zhou X, Durkin ME, Zimonjic DB, Gumundsdottir K, Eyfjord JE, Thorgeirsson SS, Popescu NC, Oncogene 2003 22 445 450 10.1038/sj.onc.1206064 12545165 (Pubitemid 36194340)
26. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Healy KD, Hodgson L, Kim TY, Shutes A, Maddileti S, Juliano RL, Hahn KM, Harden TK, Bang YJ, Der CJ, Mol Carcinog 2008 47 326 337 10.1002/mc.20389 17932950 (Pubitemid 351614573)
27. Inhibition of cell proliferation, induction of apoptosis, reactivation of DLC1, and modulation of other gene expression by dietary flavone in breast cancer cell lines. Ullmannova V, Popescu NC, Cancer Detect Prev 2007 31 110 118 10.1016/j.cdp.2007.02.005 17418982 (Pubitemid 46669816)
28. Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Beier JI, Arteel GE, Exp Biol Med (Maywood) 2012 237 1 9 10.1258/ebm.2011.011255
29. Serpins in thrombosis, hemostasis and fibrinolysis. Rau JC, Beaulieu LM, Huntington JA, Church FC, J Thromb Haemost 2007 5 Suppl 1 102 115 17635716 (Pubitemid 46958823)
30. uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases. Malinowsky K, Wolff C, Berg D, Schuster T, Walch A, Bronger H, Mannsperger H, Schmidt C, Korf U, Höfler H, Becker KF, Transl Oncol 2012 5 98 104 22496926
31. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Dorn J, Harbeck N, Kates R, Gkazepis A, Scorilas A, Soosaipillai A, Diamandis E, Kiechle M, Schmalfeldt B, Schmitt M, Ann Oncol 2011 22 877 883 10.1093/annonc/mdq462 20924077
32. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, Shariat SF, Eur Urol 2009 55 1124 1133 10.1016/j.eururo.2008.06.054 18585843
33. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K, Cancer 1996 78 487 492 10.1002/(SICI)1097- 0142(19960801)78:3<487::AID-CNCR16>3.0.CO;2-V 8697395 (Pubitemid 26250535)
34. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. Hofmann R, Lehmer A, Hartung R, Robrecht C, Buresch M, Grothe F, J Urol 1996 155 858 862 10.1016/S0022-5347(01) 66328-6 8583593 (Pubitemid 26052665)
35. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. Papadopoulou S, Scorilas A, Yotis J, Arnogianaki N, Plataniotis G, Agnanti N, Talieri M, Tumour Biol 2002 23 170 178 10.1159/000064033 12218297 (Pubitemid 44858308)
36. Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer. Cai Z, Li YF, Liu FY, Feng YL, Hou JH, Zhao MQ, Ai Zheng 2007 26 312 317 17355798
37. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer. Koensgen D, Mustea A, Denkert C, Sun PM, Lichtenegger W, Sehouli J, Anticancer Res 2006 26 1683 1689 16617562